Ashland Inc.
Financials
Valuation Metrics
Ashland Inc.'s Market Cap is $3.16B. At end of 2025 it was $2.69B. Ranked #1686 of 3,121 in US market (top 54%), #1083 of 1,658 on NYSE (top 65%), #100 of 173 in Materials (top 58%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.16B | US#1,686/3,121 Sec#100/173 |
| Revenue | $1.84B | US#1,482/3,121 Sec#99/173 |
| Net Income | $52M | US#1,873/3,121 Sec#108/173 |
| Total Assets | $4.58B | US#1,492/3,121 Sec#82/173 |
| Net Assets | $1.87B | US#1,286/3,121 Sec#85/173 |
| Employees | 2,900 | US#1,495/3,121 Sec#89/173 |
| Value | ||
| P/E | 60.76x | US#1,988/3,121 Sec#113/173 |
| P/B | 1.69x | US#1,047/3,121 Sec#63/173 |
| P/S | 1.71x | US#1,156/3,121 Sec#75/173 |
| EV/EBITDA | 10.76x | US#947/3,121 Sec#81/173 |
| FCF Yield | 6.65% | US#1,098/3,121 Sec#39/173 |
| Profitability | ||
| ROE | 2.78% | US#1,987/3,121 Sec#112/173 |
| ROA | 1.14% | US#1,931/3,121 Sec#116/173 |
| Op. Margin | 7.33% | US#1,820/3,121 Sec#106/173 |
| Revenue Growth | -1.39% | US#2,336/3,121 Sec#129/173 |
| Financial Health | ||
| Debt Ratio | 144.81% | US#1,464/3,121 Sec#123/173 |
| Total Debt | $1.48B | US#1,339/3,121 Sec#70/173 |
| FCF | $210M | US#1,362/3,121 Sec#65/173 |
| Cash | $440M | US#1,155/3,121 Sec#70/173 |
| Current Ratio | 3.05x | US#778/3,121 Sec#46/173 |
| Net Debt/EBITDA | 2.66x | US#1,505/3,121 Sec#104/173 |
| Dividend | ||
| Div. Yield | 2.41% | US#829/3,121 Sec#34/173 |
| Div. Growth | 3.79% | US#914/3,121 Sec#58/173 |
| Performance | ||
| 1Y Return | 35.16% | US#737/3,121 Sec#61/173 |
| 1M Return | -4.79% | US#1,739/3,121 Sec#114/173 |
| From 52W High | -11.82% | US#783/3,121 Sec#27/173 |
| 1Y MDD | -24.17% | US#1,010/3,121 Sec#28/173 |
| Trading | ||
| Volume | 595,701 shares | US#2,200/3,121 Sec#116/173 |
| Trading Value | $41M | US#1,646/3,121 Sec#91/173 |
| Per Share | ||
| EPS | $1.14 | US#1,637/3,121 Sec#93/173 |
| BPS | $40.84 | US#604/3,121 Sec#36/173 |
Company Info
Ashland Inc. provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally. It operates through Life Sciences, Personal Care, Specialty Additives, and Intermediates segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; and nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; agricultural chemicals; diagnostic films; and fine chemicals. Its Personal Care segment provides a range of natural, nature-derived, biodegradable, and performance ingredients; solutions for toothpastes, mouth washes and rinses, denture cleaning, and care for teeth; and household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers. The Specialty Additives segment offers rheology modifiers, foam control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, environmental filters, ingredients for the manufacturing of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals, and alloys for welding. Its Intermediates segment produces 1,4 butanediol and related derivatives, including n-methylpyrrolidone. It offers its products to customers in a range of consumer and industrial markets, such as architectural coatings, construction, energy, food and beverage, personal care, and pharmaceutical. The company was formerly known as Ashland Global Holdings Inc. and changed its name to Ashland Inc. in August 2022. Ashland Inc. was founded in 1924 and is headquartered in Wilmington, Delaware.